左美吗嗪盐酸盐 | 4185-80-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻嗪类
• 中文名称: 左美吗嗪盐酸盐
• 英文名称: levomepromazine hydrochloride
• 英文别名: hydron;3-(2-methoxyphenothiazin-10-yl)-N,N,2-trimethylpropan-1-amine;chloride
• CAS: 4185-80-2
• 化学式: C₁₉H₂₄N₂OS*ClH
• 分子量: 364.939
• InChiKey: ODLGFPIWRAEFAN-UHFFFAOYSA-N

物化性质

• 熔点：
  84-86?C
• 溶解度：
  可溶于DSMO（轻微）、甲醇（轻微）

计算性质

• 辛醇/水分配系数(LogP)：
  4.92
• 重原子数：
  24
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.37
• 拓扑面积：
  41
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险等级：
  6.1(b)
• 包装等级：
  III
• 危险类别：
  6.1(b)

反应信息

• 作为反应物：
  描述：

  左美吗嗪盐酸盐 生成 Monodesmethylmethotrimeprazin
  参考文献：
  名称：

  LOENNECHEN, T.;DAHL, S. G., J. CHROMATOGR. , 503,(1990) N, C. 205-215

  摘要：

  DOI：

文献信息

• METHOD OF TREATING A PATHOLOGICAL SYNDROME
  申请人：Epshtein Oleg Iliich

  公开号：US20160229914A1

  公开（公告）日：2016-08-11

  A method of treating disorder or condition that relates to intracellular signal transmission of a neurotransmitter, comprising administration of an homeopathically potentized form of antibodies to an antigen, which antigen is a molecule capable of effecting the intracellular signal transmission of a neuroreceptor, in particular dopamine or serotonin.

  一种治疗与神经递质的细胞内信号传递相关的疾病或症状的方法，包括给予一种高度稀释的抗原抗体制剂，该抗原是一种能够影响神经受体的细胞内信号传递的分子，特别是多巴胺或血清素。
• Nuclear Magnetic Resonance Analysis of Methotrimeprazine (Levomepromazine) Hydroxylation in Humans
  作者：Svein G. Dahl、Elisabeth Kauffmann、Bernard Mompon、Tom Purcell

  DOI：10.1002/jps.2600760710

  日期：1987.7

  Two monohydroxylated metabolites of methotrimeprazine (levomepromazine), which previously have been identified in plasma and urine from psychiatric patients, were synthesized by nonenzymatic, FeCl2-catalyzed oxidation, isolated, and purified by preparative reversed-phase HPLC. Mass spectrometric analysis gave identical spectra for the two compounds, but did not reveal the positions of the OH groups

  通过非酶催化，FeCl2催化的氧化反应合成了甲基三甲嗪（左旋丙嗪）的两种单羟基化代谢物（以前已在血浆和尿液中从精神病患者中鉴定出），并通过制备型反相HPLC进行了分离和纯化。质谱分析给出了两种化合物的相同光谱，但是没有揭示OH基团的位置。但是，在200 MHz的1H NMR光谱显示，在OV-17色谱柱上具有最短GC保留时间的一种化合物在吩噻嗪核的3位上被羟基化，而另一种衍生物则在吩噻嗪核上的3位上被羟基化。 7位。因此，甲基三甲嗪的代谢与其同类药物氯丙嗪的代谢不同，后者在人体的7位主要被羟基化。
• CURING METHOD FOR PATHOLOGIC SYNDROME AND A MEDICINAL PREPARATION
  申请人：Epshtein, Oleg Iliich

  公开号：EP1295606A1

  公开（公告）日：2003-03-26

  A method of treating a pathological syndrome includes administration of an activated form of ultra-low doses of antibodies to an antigen, wherein said activated form is obtained by repeated consecutive dilution combined with external impact, and the antigen is a substance or a pharmaceutical agent exerting influence upon the mechanisms of formation of this particular pathological syndrome. Pharmaceutical agent for treating a pathological syndrome contains activated form of ultra-low doses of monoclonal, polyclonal or natural antibodies to an antigen, wherein said activated form is prepared by means of repeated consecutive dilution and external treatment, predominantly based on homeopathic technology, and said antigen is a substance or a drug acting as a direct cause of the pathological syndrome or involved in regulation of mechanisms of its formation. At that, activated forms of ultra-low doses of antibodies are raised against antigens of exogenous or endogenous origin, against autologous antigens, fetal antigens; anti-idiotypic antibodies are used too.

  一种治疗病理综合征的方法，包括给药超低剂量抗原抗体的活化形式，其中所述活化形式是通过反复连续稀释结合外部影响获得的，抗原是对该特定病理综合征的形成机制有影响的物质或药剂。 治疗病理综合征的药剂包含超低剂量的抗原单克隆抗体、多克隆抗体或天然抗体的活化形式，其中所述活化形式是通过反复连续稀释和外部处理的方法制备的，主要基于顺势疗法技术，所述抗原是作为病理综合征的直接原因或参与调节其形成机制的物质或药物。在这种情况下，针对外源性或内源性抗原、自体抗原、胎儿抗原的超低剂量抗体活化形式就会产生。
• Curing method for pathologic syndrome and medicinal preparation
  申请人：——

  公开号：US20030099636A1

  公开（公告）日：2003-05-29

  A method of treating a pathological syndrome includes administration of an activated form of ultra-low doses of antibodies to an antigen, wherein said activated form is obtained by repeated consecutive dilution combined with external impact, and the antigen is a substance or a pharmaceutical agent exerting influence upon the mechanisms of formation of this particular pathological syndrome. Pharmaceutical agent for treating a pathological syndrome contains activated form of ultra-low doses of monoclonal, polyclonal or natural antibodies to an antigen, wherein said activated form is prepared by means of repeated consecutive dilution and external treatment, predominantly based on homeopathic technology, and said antigen is a substance or a drug acting as a direct cause of the pathological syndrome or involved in regulation of mechanisms of its formation. At that, activated forms of ultra-low doses of antibodies are raised against antigens of exogenous or endogenous origin, against autologous antigens, fetal antigens; anti-idiotypic antibodies are used too.

  一种治疗病理综合征的方法，包括给药超低剂量抗原抗体的活化形式，其中所述活化形式是通过反复连续稀释结合外部影响获得的，抗原是对该特定病理综合征的形成机制有影响的物质或药剂。 治疗病理综合征的药剂包含超低剂量的抗原单克隆抗体、多克隆抗体或天然抗体的活化形式，其中所述活化形式是通过反复连续稀释和外部处理的方法制备的，主要基于顺势疗法技术，所述抗原是作为病理综合征的直接原因或参与调节其形成机制的物质或药物。在这种情况下，针对外源性或内源性抗原、自体抗原、胎儿抗原的超低剂量抗体活化形式就会产生。
• IRIE, TETSUMI;OTAGIRI, MASAKI;UEKAMA, KANETO;YONEDA, FUMIO;KUSU, FUMIYO;T+, J. CHEM. SOC. JAP., CHEM. AND IND. CHEM., 1983, N 2, 219-224
  作者：IRIE, TETSUMI、OTAGIRI, MASAKI、UEKAMA, KANETO、YONEDA, FUMIO、KUSU, FUMIYO、T+

  DOI：——

  日期：——

表征谱图